Sorafenib    (DrugBank: Sorafenib)

2 diseases
IDDisease name (Link within this page)Number of trials
34Neurofibromatosis2
86Pulmonary arterial hypertension2

34. Neurofibromatosis    [ 120 clinical trials,   182 drugs,   (DrugBank: 72 drugs),   84 drug target genes,   194 drug target pathways]
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 120 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-001789-16-GB
(EUCTR)
26/08/201117/05/2011Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas - Sorafenib in NF2Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas - Sorafenib in NF2 Neurofibromatosis, type 2 (acoustic neurofibromatosis)
MedDRA version: 14.0;Level: LLT;Classification code 10029271;Term: Neurofibromatosis, type 2 (acoustic neurofibromatosis);System Organ Class: 10010331 - Congenital, familial and genetic disorders
Plymouth Hospital NHS TrustNULLNot Recruiting Female: yes
Male: yes
14Phase 4United Kingdom
2NCT00727233
(ClinicalTrials.gov)
July 8, 200831/7/2008Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform NeurofibromasPhase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform NeurofibromasNeurofibromatosis Type I;Plexiform NeurofibromaDrug: Nexavar (BAY 43-9006) (Sorafenib);Drug: Toxicity, Pharmacokinetics;Drug: Pharmacodynamics;Drug: Radiographic Evaluation;Drug: QOL assessment, Neuropsychological;Drug: Bony ToxicityNational Cancer Institute (NCI)NULLCompleted3 Years18 YearsAll9Phase 1United States

86. Pulmonary arterial hypertension    [ 1,083 clinical trials,   667 drugs,   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways]
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,083 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000001709
2009/02/0116/02/2009Multikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial Hypertension pulmonary arterial hypertensionadministration of sorafenib, which is the multikinase inhibitor (tyrosine and serine/threonine kinase inhibitor)Medical Education Center, School of Medicine, Keio UniversityNULLPending20years-oldNot applicableMale and Female10Not selectedJapan
2NCT00452218
(ClinicalTrials.gov)
March 200726/3/2007Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial HypertensionDrug: SorafenibUniversity of ChicagoBayerCompleted18 YearsN/ABoth12Phase 1United States